Cancer cell lines are major model systems for mechanistic investigation and drug development. However, protein expression data linked to high-quality DNA, RNA, and drug-screening data have not been available across a large number of cancer cell lines. Using reverse-phase protein arrays, we measured expression levels of ∼230 key cancer-related proteins in |650 independent cell lines, many of which have publically available genomic, transcriptomic, and drug-screening data.
An antibody microarray (also known as antibody array) is a specific form of protein microarray. In this technology, a collection of capture antibodies are spotted and fixed on a solid surface such as glass, plastic, membrane, or silicon chip, and the interaction between the antibody and its target antigen is detected. Antibody microarrays are often used for detecting protein expression from various biofluids including serum, plasma and cell or tissue lysates. Antibody arrays may be used for both basic research and medical and diagnostic applications. The concept and methodology of antibody microarrays were first introduced by Tse Wen Chang in 1983 in a scientific publication and a series of patents, when he was working at Centocor in Malvern, Pennsylvania. Chang coined the term "antibody matrix" and discussed "array" arrangement of minute antibody spots on small glass or plastic surfaces. He demonstrated that a 10×10 (100 in total) and 20×20 (400 in total) grid of antibody spots could be ...
... ,Ciphergens ProteinChip arrays have been developed for affinity capture of proteins from biological samples. A variety of ProteinChip chemical surfaces allow differential capture of proteins according to their unique biochemical properties. Each chip has eight different spots, allowing side-by-side,biological,biology supply,biology supplies,biology product
... ,Ciphergens ProteinChip arrays have been developed for affinity capture of proteins from biological samples. A variety of ProteinChip chemical surfaces allow differential capture of proteins according to their unique biochemical properties. Each chip has eight different spots, allowing side-by-side,biological,biology supply,biology supplies,biology product
TY - JOUR. T1 - Rapid identification of monospecific monoclonal antibodies using a human proteome microarray.. AU - Jeong, Jun Seop. AU - Jiang, Lizhi. AU - Albino, Edisa. AU - Marrero, Josean. AU - Rho, Hee Sool. AU - Hu, Jianfei. AU - Hu, Shaohui. AU - Vera, Carlos. AU - Bayron-Poueymiroy, Diane. AU - Rivera-Pacheco, Zully Ann. AU - Ramos, Leonardo. AU - Torres-Castro, Cecil. AU - Qian, Jiang. AU - Bonaventura, Joseph. AU - Boeke, Jef D.. AU - Yap, Wendy Y.. AU - Pino, Ignacio. AU - Eichinger, Daniel J.. AU - Zhu, Heng. AU - Blackshaw, Seth. PY - 2012/6. Y1 - 2012/6. N2 - To broaden the range of tools available for proteomic research, we generated a library of 16,368 unique full-length human ORFs that are expressible as N-terminal GST-His(6) fusion proteins. Following expression in yeast, these proteins were then individually purified and used to construct a human proteome microarray. To demonstrate the usefulness of this reagent, we developed a streamlined strategy for the production of ...
Protein tyrosine kinases (PTKs) play pivotal roles in human cancer and are the targets of a major class of emerging anti-cancer drugs. In a single tumor, multiple PTKs are active and a substantial number are essential for maintaining the transformed phenotype. Though large numbers of phosphorylation sites have been mapped in cancer cells through mass spectrometry (MS), the identity of the specific kinases that phosphorylate these sites are with very few exceptions unknown. We propose to use emerging peptide microarray technology to identify consensus phosphorylation sequences for the entire set of human PTKs. We will generate a set of mammalian expression vectors producing every PTK fused to glutathione S-transferase. Each PTK will be affinity purified from a mammalian cell overexpression system and subjected to peptide microarray screening. These screens will reveal specific sequences preferred by each kinase at phosphorylation sites in their target substrates. We will use this data to mine ...
A major challenge in human DCIS research has been the identification of markers associated with the transition from DCIS to invasive breast carcinoma. Progress toward achieving this goal could be enhanced by using advanced microarray techniques to measure the humoral response against the cancer. In this study, we successfully used protein microarray technology to identify an autoantibody signature in patients with preinvasive and early invasive breast cancer. In doing so, we identified a subset of 5 autoantibodies that can accurately distinguish between the groups. These data suggest that autoantibody detection could serve as a new prognostic test.. Surprisingly, the autoantigens identified in this study were different from previously identified DCIS-associated TAAs (12, 15-17). Substantial differences exist between protein microarrays and other techniques used to identify TAAs. The ProtoArray protein microarrays contain proteins that are expressed in insect cells and, therefore, contain ...
Protein microarrays provide an efficient method to recognize and quantify protein-protein connections in great throughput. will end up being described at length in the protocols beneath. Measuring binding affinities acts at least three reasons. First the excess rigor necessary to quantify connections minimizes the quantity of wrong details in the ultimate NVP-BAG956 data set. Many high-throughput methods have got alarmingly high prices of fake positives and fake negatives22-25 restricting their effectiveness in generating natural hypotheses. Second identifying binding affinities really helps to prioritize which connections will end up being biologically relevant. Finally quantitative information pays to for modeling studies targeted at predicting protein-protein interactions especially. Furthermore to offering binding affinities proteins microarrays also enable someone to assess how well a ligand is normally acknowledged by every person in a proteins family. As such they offer details on binding ...
TY - JOUR. T1 - Advances in cell-free protein array methods. AU - Yu, Xiaobo. AU - Petritis, Brianne. AU - Duan, Hu. AU - Xu, Danke. AU - LaBaer, Joshua. PY - 2018/1/2. Y1 - 2018/1/2. N2 - Introduction: Cell-free protein microarrays represent a special form of protein microarray which display proteins made fresh at the time of the experiment, avoiding storage and denaturation. They have been used increasingly in basic and translational research over the past decade to study protein-protein interactions, the pathogen-host relationship, post-translational modifications, and antibody biomarkers of different human diseases. Their role in the first blood-based diagnostic test for early stage breast cancer highlights their value in managing human health. Cell-free protein microarrays will continue to evolve to become widespread tools for research and clinical management. Areas covered: We review the advantages and disadvantages of different cell-free protein arrays, with an emphasis on the methods ...
phdthesis{34b38b30-7926-4d3b-be18-4e6e97c97e27, abstract = {Antibody-based microarrays are among the novel class of rapidly evolving proteomic technologies. In recent years, antibody microarrays have emerged as a unique tool for high-throughput protein expression profiling with great promise within biomedicine and a wide range of potential applications, including disease diagnostics and biomarker discovery. In order to evolve the technology from small dedicated microarrays to high-density well-performing arrays for true global proteome analysis, this thesis focussed on the design of the two key components of the antibody microarray setup: the probe and the solid support, i.e. ?catcher and carrier?. The thesis is based upon five original papers that deal with i) the central features of the probe (on-chip functionality and stability, sensitivity and immobilisation strategies) and ii) the biocompatibility of the solid support (defined by the spot morphology, binding capacity, signal to noise ratio, ...
Background. Activating mutations in FLT3 are frequent in acute myeloid leukemia and represent both a poor prognostic feature and therapeutic target. We have identified a previously unrecognized downstream effect of FLT3 activation, namely upregulation of the homeodomain genes, DLX1 and DLX2. Design and Methods. MV4;11 cells with FLT3/ITD mutation, RS4;11 cells with wild-type FLT3 and AML patient blasts were used to pursue the relation between FLT3, DLX1/2 and TGFbeta. Quantitative RT-PCR, Western blot and reverse-phase protein array were performed to detect changes in gene and protein expression. RNA interference and MTS assay studied the interaction of PKC412, FLT3 inhibitor and TGFbeta. Results. A direct relationship between FLT3 activity and DLX1/2 expression was revealed by both inhibition and upregulation of FLT3 signaling in MV4;11 and RS4;11 cell lines, respectively, in isolated blast cells from patients with acute myeloid leukemia, and in large reverse-phase protein array from patient ...
Joshua L. LaBaer, interim executive director of the Biodesign Institute at Arizona State University Download Full Image His efforts involve the discovery and validation of biomarkers - unique molecular fingerprints of disease - that can provide early warning for those at risk of major illnesses, including cancer and diabetes. Much of his work concerns proteomics, a branch of biotechnology concerned with analyzing the structure, function and interactions of the proteins produced by the genes of cells, tissues or organisms. His research is recognized as extremely relevant and impactful for a number of chronic health conditions, with direct application from bench to bedside. LaBaer was recruited to the ASU Biodesign Institute as the first Piper Chair in Personalized Medicine in 2009. His group, the Virginia G. Piper Center for Personalized Diagnostics, invented a novel protein microarray technology, Nucleic Acid Programmable Protein Array, which has been used widely for biomedical research. Its use ...
Introduction to microarray technologies / Robert S. Matson -- Nucleic acid sample preparation / Robert S. Matson -- Solid-phase substrates for nucleic acid microarrays / Robert S. Matson -- Protein sample preparation for microarrays / Robert S. Matson -- Solid-phase chemistries for protein microarrays / Robert S. Matson -- Protein microarrays : the link between genomics and proteomics / Persis P. Wadia and David B. Miklos -- Bead arrays : an introduction to multiplexed bead-based assays for proteins / Yong Song -- Carbohydrate arrays / Denong Wang -- Lectin microarrays / Masao Yamada -- Printing methods / Todd Martinsky.;Introduction to microarray technologies / by Robert S. Matson -- Nucleic acid sample preparation / by Robert S. Matson -- Solid-phase substrates for nucleic acid microarrays / by Robert S. Matson -- Protein sample preparation for microarrays / by Robert S. Matson -- Solid-phase chemistries for protein microarrays / by Robert S. Matson -- Protein microarrays by / David B. Miklos ...
Reverse Phase Protein Arrays (RPPA). RPPA are a high-throughput antibody-based technique developed for Functional Proteomics studies to evaluate protein activities in signaling networks.. At present, more then 400 antibodies have been validated for the use in the RPPA Platform. These antibodies cover all the major protein pathways in the cell:. ...
Design of experiment (DOE) was utilized to optimize a peptide microarray to test autoantibodies in serum against various components of the myelin sheath. Incorporating the ideal assay conditions from a single DOE experiment versus multiple sequential experiments resulted in a reproducible serum assay with low variability, low nonspecific background, and a high level of distinction between multiple sclerosis (MS) and normal samples. A minimum set of peptides was found that achieved a sensitivity of 90 percent. Autoantibodies against each individual peptide were elevated in at least 35 percent of the individual MS patients tested. ...
Design of experiment (DOE) was utilized to optimize a peptide microarray to test autoantibodies in serum against various components of the myelin sheath. Incorporating the ideal assay conditions from a single DOE experiment versus multiple sequential experiments resulted in a reproducible serum assay with low variability, low nonspecific background, and a high level of distinction between multiple sclerosis (MS) and normal samples. A minimum set of peptides was found that achieved a sensitivity of 90 percent. Autoantibodies against each individual peptide were elevated in at least 35 percent of the individual MS patients tested. ...
Specifying 14-3-3: A fragment-based combinatorial peptide microarray generates affinity-based fingerprints of seven mammalian 14-3-3 isoforms. High-affinity motifs are identified against the highly homologous isoforms. Putative 14-3-3σ-specific peptides were also delineated by a dual-color ratiometric screening strategy (see picture). (Figure Presented) © 2008 Wiley-VCH Verlag GmbH & Co. KGaA ...
Carbohydrate post-translational modifications on proteins are important determinants of protein function in both normal and disease biology. We have developed a method to allow the efficient, multiplexed study of glycans on individual proteins from complex mixtures, using antibody microarray capture …
ABM supplies a variety of different premade protein lysate products. You are currently viewing page 1 of the letter O gene protein lysate.
IMPFSTOFFE + VAKZINE (PHARMAZIE); OBERFLÄCHENANTIGENE (IMMUNOLOGIE); ORGANISCHE SYNTHESE (CHEMIE); PROTEIN-MIKROARRAY-TECHNOLOGIE (MOLEKULARGENETISCHE TECHNIKEN); VACCINES (PHARMACY); SURFACE ANTIGENS (IMMUNOLOGY); ORGANIC SYNTHESIS (CHEMISTRY); PROTEIN MICROARRAY TECHNOLOGY (MOLECULAR GENETIC TECHNIQUES ...
The antigen proteome microarray and immunoprofiling platform partners high throughput technology expedites biomarker and vaccine target discovery by measuring antibody responses to thousands of proteins in a single assay. Protein expression is carried out on a proteome level allowing the entire proteome to be screened for antigen targets using a small volume of biological samples. The partners library contains over 60,000 expressible Open Reading Frame (ORF) clones representing more than 50 medically important infectious disease causing organisms and human proteins. These clones can be used for the manufacture of protein microarrays.. Applications of the technology: ...
Methods for identifying biomarkers, autoantibody signatures, and stratifying subject groups using peptide arrays - diagram, schematic, and image 20 ...
Reverse-phase protein arrays (RPPA) represent a powerful functional proteomic approach to elucidate cancer-related molecular mechanisms and to develop novel cancer therapies. To facilitate community-based investigation of the large-scale protein expression data generated by this platform, we have developed a user-friendly, open-access bioinformatic resource, The Cancer Proteome Atlas (TCPA, http://tcpaportal.org), which contains two separate web applications.
SH2 protein microarray assays of HA4 specificity(a) Fluorescence images of SH2 chips following incubation with fluorophore-labeled HA4. Each SH2 domain is spott
A system-wide analysis of cell signaling requires detecting and quantifying many different proteins and their posttranslational modification states in the same cellular sample. Here, we present Protocols for two miniaturized, array-based methods, one of which provides detailed information on a central signaling protein and the other of which provides a broad characterization of the surrounding signaling network. We describe a bead-based array and its use in characterizing the different forms and functions of β-catenin, as well as lysate microarrays (reverse-phase protein arrays) and their use in detecting and quantifying proteins involved in the canonical and noncanonical Wnt signaling pathways. As an application of this dual approach, we characterized the state of β-catenin signaling in cell lysates and linked these molecule-specific data with pathway-wide changes in signaling. The Protocols described here provide detailed instructions for cell culture methods, bead arrays, and lysate ...
Purpose: The current study evaluated associative effects of breast cancer cells with the tumor microenvironment and its influence on tumor behavior. Experimental design: Formalin-fixed paraffin embedded tissue and matched protein lysates were evaluated from two independent breast cancer patient data sets (TCGA and MD Anderson). Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to determine markers that were differentially expressed in stroma and cancer cells. Protein localization and stromal contents were evaluated for matched cases by imaging. Results: A subtype of breast cancers designated "Reactive," previously identified by RPPA that was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily estrogen receptor (ER)-positive/human epidermal growth factor receptor (HER)2-negative, low-risk cancers as determined by ...
Protein tyrosine phosphorylation controls many aspects of signaling in multicellular organisms. One of the major consequences of tyrosine phosphorylation is the creation of binding sites for proteins containing Src homology 2 (SH2) domains. To profile the global tyrosine phosphorylation state of the cell, we have developed proteomic binding assays encompassing nearly the full complement ofhuman SH2 domains. Here we provide a global view of SH2 domain binding to cellular proteins based on large-scale far-western analyses. We also use reverse-phase protein arrays to generate comprehensive, quantitative SH2 binding profiles for phosphopeptides, recombinant proteins, and entire proteomes. As an example, we profiled the adhesion-dependent SH2 binding interactions in fibroblasts and identified specific focal adhesion complex proteins whose tyrosine phosphorylation and binding to SH2 domains are modulated by adhesion. These results demonstrate that high-throughput comprehensive SH2 profiling provides valuable
Saenz, D.T., Fiskus, W., Manshouri, T. et al.. Myeloproliferative Neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of JAK-STAT signaling, which responds to treatment with the JAK1 & 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary AML (sAML), where standard induction chemotherapy or ruxolitinib is relatively ineffective, necessitating the development of novel therapeutic approaches. In the present studies, we demonstrate that treatment with BET (bromodomain and extra terminal) protein inhibitor (BETi), e.g., JQ1, inhibits growth and induces apoptosis of cultured and primary, patient-derived (PD), post-MPN sAML blast progenitor cells. Reverse-phase protein array, mass-cytometry and Western analyses revealed that BETi treatment attenuated the protein expressions of c-MYC, p-STAT5, Bcl-xL, CDK4/6, PIM1 and IL-7R, while concomitantly inducing the levels of HEXIM1, p21 and BIM in the sAML cells. Co-treatment with BETi and ruxolitinib ...
BACKGROUND: In 2016, it is estimated that there will be 62,700 new cases of kidney cancer in the United States, and 14,240 patients will die from the disease. Because the incidence of kidney renal clear cell carcinoma (KIRC), the most common type of kidney cancer, is expected to continue to increase in the US, there is an urgent need to find effective diagnostic biomarkers for KIRC that could help earlier detection of and customized treatment strategies for the disease. Accordingly, in this study we systematically investigated KIRCs prognostic biomarkers for survival using the reverse phase protein array (RPPA) data and the high throughput sequencing data from The Cancer Genome Atlas (TCGA ...
Cancer patients with undetectable micrometastases at the time of diagnosis are in danger of subsequent metastatic growth that worsens their outcome. Therefore, identification of these patients with latent metastases could reduce morbidity and mortality by helping physicians to choose whether to treat with an adjuvant therapy. In colorectal carcinoma (CRC), 20-30% of stage II patients will have a recurrence at a distant site after removal of the primary tumor. In order for cancer cells to metastasize, they must switch to an "invasive phenotype". To identify molecular changes in cancer that drive invasion, our laboratory previously built a molecular network model of invasive subcellular structures termed invadopodia. Centrality and random walk analyses identified candidate signaling hubs that may control invadopodia formation or activity. To identify which of these hubs control invasion in specific cancers, we are mining reverse phase protein array (RPPA) data from publicly available human tumor ...
Our key platforms support gene discovery through gene suppression (RNAi) or gene knockout (CRISPR) strategies, generally coupled with detailed quantitative cellular phenotypic high content imaging. Quantitation of protein expression and posttranslational modification is also available through the Reverse Phase Protein Array platform with over 100 antibodies available for analysis in our collection, which continues to expand.. ...
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Monkey Adult Tissues Protein lysate, Universal \ MKUL-4569 for more molecular products just contact us
Background We survey here a fresh type of proteins chip to detect antibodies in sera. sufferers, however, not in HCV-negative sera. Bottom PTC124 line This proteins chip program may possess useful properties to fully capture a specific group of antibodies for predicting the onset of particular malignancies such as for example HCC in HCV-infected people. BL21 stress. All protein were built to include a six-histidine (6xHis)-fused GFP-tag (26?kDa) on the N-terminus and a 5Cys-tag on the C-terminus. A 6His-GFP-5Cys build without fusion partner (31?kDa) was used being a control. The N-terminal part of HSP70 (HSP70N; 42?kDa) containing the ATPase area and C-terminal part (HSP70C; 29?kDa) containing the substrate-binding area were expressed separately. SOD2 (22?kDa) and PRDX6 (25?kDa) were expressed as entire protein. The appearance of recombinant GFP-tagged antigenic protein were verified by SDS-PAGE after purification using Ni-affinity gel (Body? 2A). The proteins had been published on 3??3?mm ...
Results In the cohort of 26 patients 1292 different autoantigens (IgD,IgA,IgG) were detected. Using protein array we investigated clusters of autoantigen responses that disappeared or developed during RTX treatment of RA patients. RA autoantigenic patterns before and 6 month after RTX treatment were patient-specific and no relevant autoantigenic cluster was found that was shared between patients or associated with response. However, RTX reduced the repertoire of autoantibodies after 24 weeks of treatment in the tested RA patient cohort on average by 60%. RA patients which do not respond are generating on average 63% new autoantibodies. In good responders to RTX only 5,5% (+/-3%) new autoantibodies can be detected. The IgA and IgG autoantibody repertoire in the serum after 24 weeks of RTX treatment is reduced (IgA: 41%, IgG: 31%) in good responders whereas it is increased (IgA: 1,3%, IgG: 24%) in non responders to RTX. ...
Arrayit offers microarray software and microarray books as tools and resources to facilitate the use of Arrayit microarray products and microarray services. Array Designer software, T-shirts, Beginners Guide to Microarrays, DNA Microarrays A Practical Approach, DNA Array Image Analysis Nuts & Bolts, DNA Microarrays Methods Express, Microarray Analysis, Microarray Biochip Technology, Microarrays Methods and Applications, and Protein Microarrays are among the microarray products Arrayit offers in furtherance of microarray research.
The proteins are arrayed onto a solid surface such as microscope slides, membranes, beads or microtitre plates. The function of this surface is to provide a support onto which proteins can be immobilized. It should demonstrate maximal binding properties, whilst maintaining the protein in its native conformation so that its binding ability is retained. Microscope slides made of glass or silicon are a popular choice since they are compatible with the easily obtained robotic arrayers and laser scanners that have been developed for DNA microarray technology. Nitrocellulose film slides are broadly accepted as the highest protein binding substrate for protein microarray applications. The chosen solid surface is then covered with a coating that must serve the simultaneous functions of immobilising the protein, preventing its denaturation, orienting it in the appropriate direction so that its binding sites are accessible, and providing a hydrophilic environment in which the binding reaction can occur. ...
Protein binding microarrays (PBM) are a high throughput technology used to characterize protein-DNA binding. The arrays measure a proteins affinity toward thousands of double-stranded DNA sequences at once, producing a comprehensive binding specificity catalog. We present a linear model for predicting the binding affinity of a protein toward DNA sequences based on PBM data. Our model represents the measured intensity of an individual probe as a sum of the binding affinity contributions of the probes subsequences. These subsequences characterize a DNA binding motif and can be used to predict the intensity of protein binding against arbitrary DNA sequences. Our method was the best performer in the Dialogue for Reverse Engineering Assessments and Methods 5 (DREAM5) transcription factor/DNA motif recognition challenge. For the DREAM5 bonus challenge, we also developed an approach for the identification of transcription factors based on their PBM binding profiles. Our approach for TF identification ...
d) Another significant issue with the study is the transfer between different platforms, which introduces further uncertainties. In brief, antigens were selected based on the results of a proteome microarray done in a previous study. These antigens were then expressed (primarily in E coli.) and purified, while other antigens used in the study were native antigen preparations. The antigens were then used in 1. Luminex-based assays, and 2. the MBio immunoassay. Undoubtedly there is the potential for technical issues along the way: a) the antigens expressed in E. coli could have a different structure or conformation than the antigens used in the proteome microarray, b) the epitope orientation of antigens used in the Luminex and MBio arrays may have been suboptimal, c) the MBio arrays themselves may be insufficiently sensitive/robust. In other words, while TB-specific antibodies may have been present in the samples of the active TB cases, they may have not been detected due to technical issues ...
MacBeath and Schreiber carried out three types of controls on their microarray slides. In one, they detected the binding of three protein pairs, each previously known to interact. In this experiment they deposited a 100 μg/ml solution of one member of the pair onto a glass slide, then incubated it with 0.1-0.5 μg/ml of the other protein in the pair. The latter was fluorescently labeled, so the slide was passed under a fluorimeter to detect binding. Specific binding was observed, even in a single droplet of one target protein on a slide containing 10,799 droplets of another protein. In the second control, the authors detected phosphorylation activity in three protein pairs, each known to be a kinase and complementary substrate. Kinase solutions and labeled ATP were incubated with glass slides dotted with substrate droplets (concentrations are not given in the article). Labeled phosphate was observed in the droplets, and phosphorylation was specific. In the third control, binding of three pairs ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
In vitro transcription/translation (IVTT) systems are widely used in proteomics. For clinical applications, mammalian systems are preferred for protein folding and activity; however, the level of protein obtained is low. A new system extracted from human cells (1-Step Human Coupled IVT (HCIVT)) has the potential to overcome this problem and deliver high yields of protein expressed in a human milieu.. Western blots and self-assembled protein microarrays were used to test the efficiency of protein synthesis by HCIVT compared to rabbit reticulocyte lysate (RRL). The arrays were also used to measure the immune response obtained from serum of patients exposed to pathogens or vaccine.. HCIVT performed better than RRL in all experiments. The yield of protein synthesized in HCIVT is more than ten times higher than RRL, in both Western blot and protein microarrays. Moreover, HCIVT showed a robust lot-to-lot reproducibility. In immune assays, the signals of many antigens were detected only in ...
A guided material screening approach to develop sol-gel derived protein doped microarrays using an emerging pin-printing method of...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Inflammation (Human) Quantitative Antibody Array 1 is a multiplex antibody array for the quantitative measurement of 10 human cytokines in 8-10 samples. related publications, related pathways and related gentaur products
Sciomics: highly parallel protein analyses with antibody microarrays for pathway profiling, biomarker discovery and verification.
Alongside the increasing availability of affinity reagents, antibody microarrays have been developed to become a powerful tool to screen for target proteins in complex samples. Besides multiplexed sandwich immunoassays, the application of directly applying labeled sample onto arrays with immobilized capture reagents offers an approach to facilitate a systematic, high-throughput analysis of body fluids such as serum or plasma. An alternative to commonly used planar arrays has become available in form of a system based on color-coded beads for the creation of antibody arrays in suspension. The assay procedure offers an uncomplicated option to screen larger numbers of serum or plasma samples with variable sets of capture reagents. In addition, the established procedure of whole sample biotinylation circumvents the purification steps, which are generally required to remove excess labeling substance. We have shown that this assay system allows detecting proteins down into lower pico-molar and higher ...
Protein arrays for the parallel, in vitro screening of biomolecular activity are provided. Methods of using the protein arrays are also disclosed. On the arrays, a plurality of different proteins, such as different members of a single protein family, are immobilized on one or more organic thinfilms on the substrate surface. The protein arrays are particularly useful in drug development, proteomics, and clinical diagnostics.
Hajime Mori of Kyoto Institute of Technology in Japan will develop protein chips that encapsulate poliovirus-like particles (PLP) for use as a safe and effective polio vaccine. When the PLP-protein chips are orally administered, they pass through the stomach without degradation and then are gradually released into the gut to induce a strong immunity against poliovirus infection.. ...
The Bio-ID is the worlds first platform to integrate Inanovates patented LAS technology. The Bio-ID is a multiplexed protein quantification platform which, in real-time, measures protein concentrations from complex matrices. The instrument combines high sensitivity confocal imaging and microfluidics alongside protein based microarrays, resulting in a novel solution to the problems associated with existing state-of-the-art multiplexed platforms.. Instead of depending on a 96-well micro-titer plate, the Bio-ID utilizes a glass slide based protein microarray combined with microfluidics for dispensing and binding samples and detection antibodies. A typical Bio-ID cartridge is shown in the photo to the below right.. In its most basic form, the protein microarray is composed of capture antibodies for the proteins (analytes) being measured, as well as positive and negative quality control features for ensuring sample to sample, run to run, lot to lot, and user to user consistency.. Conceptually ...
The Bio-ID is the worlds first platform to integrate Inanovates patented LAS technology. The Bio-ID is a multiplexed protein quantification platform which, in real-time, measures protein concentrations from complex matrices. The instrument combines high sensitivity confocal imaging and microfluidics alongside protein based microarrays, resulting in a novel solution to the problems associated with existing state-of-the-art multiplexed platforms.. Instead of depending on a 96-well micro-titer plate, the Bio-ID utilizes a glass slide based protein microarray combined with microfluidics for dispensing and binding samples and detection antibodies. A typical Bio-ID cartridge is shown in the photo to the below right.. In its most basic form, the protein microarray is composed of capture antibodies for the proteins (analytes) being measured, as well as positive and negative quality control features for ensuring sample to sample, run to run, lot to lot, and user to user consistency.. Conceptually ...